1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Venmax Drugs & Pharmaceuticals Ltd.

Venmax Drugs & Pharmaceuticals Ltd.

BBSE:VENMAX
14.50
INR
-0.49
(-3.27%)
0.30EPS
60.95P/E
214.17MMarket Cap
Venmax Drugs & Pharmaceuticals Ltd.
BSE:VENMAX
(Bombay Stock Exchange)

Recent

price

14.50

P/E

ratio

60.95

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
INR
1.89
6.33
8.19
1.12
4.55
3.69
0.49
- -
0.29
0.9
0.32
- -
- -
- -
1.54
6.93
10.06
Revenue per Share
-0.93
-1.81
-0.23
-4.39
-0.15
-0.26
-2.55
-0.46
-0.45
-0.52
-0.31
3.52
0.43
0.12
-0.02
0.21
0.3
Basic EPS, GAAP
- -
- -
- -
1.63
-0.19
-0.36
-2.01
-0.49
-0.32
-0.53
0.5
3.64
-0.01
- -
-4.37
-9.49
-13.15
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
5.18
0.8
0.64
-0.84
-3.57
-4.03
-4.49
-5.01
-5.32
-1.79
-1.36
-1.24
8.42
12.19
12.96
Book Value per Share
- -
- -
5.18
0.8
0.64
-0.84
-3.57
-4.03
-4.55
-5.07
-5.37
-1.84
-1.41
-1.29
8.42
12.19
12.96
Tangible Book Value per Share
9
3
5
5
5
5
5
5
5
5
5
5
5
5
5
12
9
Basic Weighted Avg Shares
18
22
43
6
24
19
3
- -
2
5
2
- -
- -
- -
8
80
93
Sales/Revenue/Turnover
-7.28
-23.66
-20.04
-74.45
-4.74
-7.14
-24.52
- -
-161.38
-56.59
-204.38
- -
- -
- -
-132.19
1.45
1.6
Operating Margin (%)
2
2
2
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
-9
-6
-1
-23
-1
-1
-13
-2
-2
-3
-2
18
2
1
- -
2
3
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.02
0.04
25.73
- -
10.36
9.34
Effective Tax Rate (%)
-49.13
-28.59
-2.85
-391.5
-3.29
-7.14
-515.41
- -
-156.82
-57.94
-96.78
- -
- -
- -
-1.3
3.09
3.02
Profit Margin (%)
- -
- -
-18
- -
- -
-14
-19
-21
-25
-27
-29
-10
-8
-7
44
141
150
Working Capital
- -
- -
24
14
15
17
18
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
- -
- -
27
4
3
-4
-19
-21
-24
-26
-28
-9
-7
-7
44
141
150
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1.1
1.37
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-352.2
-47.32
-19.53
- -
2.63
2.86
Return on Capital (%)
- -
- -
- -
-146.77
-21.22
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
2.68
2.89
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
33
3
2
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
8
12
12
Market Capitalization
200
298
214

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
194
162
168
Cash, Cash Equivalents & STI
14
86
127
Accounts Receivable, Net
53
14
16
Inventories
16
10
22
Total Current Liabilities
100
20
18
Payables & Accruals
- -
- -
- -
ST Debt
33
3
2
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-29.27%
-131.59%
219.96%
Free Cash Flow
-10,324.19%
-20,693.81%
380.13%
Net Income, GAAP
-321.59%
-795.13%
-2,463.81%
Sales/Revenue/Turnover
- -
- -
894.04%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
1
2
2
3
8
2026
12
13
16
39
80
2027
25
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
0.02
-0.58
-0.95
1.49
-0.02
2026
0.07
0.03
0.05
0.09
0.21
2027
0.1
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Venmax Drugs & Pharmaceuticals Ltd. is an India-based pharmaceutical enterprise engaged in the development, manufacturing, marketing, and distribution of active pharmaceutical ingredients (APIs), bulk drugs, advanced chemical intermediates, and finished pharmaceutical formulations. Founded in 1988 and headquartered in Hyderabad, Telangana, the company operates within the healthcare and life sciences industry, serving domestic formulation manufacturers, commercial healthcare distributors, institutional buyers, and select international export markets across Asia and Africa. The company offers a comprehensive product and service portfolio across human and veterinary therapeutic segments, comprising: active pharmaceutical ingredients and bulk drugs, including Ciprofloxacin Hydrochloride, Norfloxacin, Ofloxacin, Enrofloxacin, Ampicillin Trihydrate, and Amoxicillin Trihydrate; advanced chemical intermediates, such as fluoroquinolone derivatives, piperazine derivatives, pyridine intermediates, and ethyl ester precursors; generic finished dosage forms, including oral solid tablets, hard-gelatin capsules, dry syrups, and liquid oral suspensions; veterinary active compounds and animal healthcare formulations; and contract development, custom chemical synthesis, and third-party contract manufacturing services for external pharmaceutical partners. In recent developments, Venmax Drugs & Pharmaceuticals Ltd. has executed several operational and strategic initiatives to strengthen its market position and optimize production efficiency. Over the past two years, the company has undertaken facility modernization and technological upgrades to comply with revised Schedule M and current Good Manufacturing Practice (cGMP) regulatory benchmarks; expanded its domestic trade distribution network to accelerate the commercialization of high-demand generic formulations; pursued strategic contract manufacturing alliances with regional pharmaceutical marketers; and initiated internal organizational reorganizations alongside capital structure optimizations to support business expansion into higher-margin therapeutic categories.